Navigation Links
Study examines new class of anticoagulants for VTE prevention and treatment

ANN ARBOR, Mich., Dec. 11, 2013 /PRNewswire-USNewswire/ --- The University of Michigan has been awarded $1.7 million to collaborate with GlycoMimetics, Inc., to study a new class of anticoagulants to help millions of Americans at risk or venous thromboembolic disease (VTE), a serious blood-clotting disorder.

The National Heart Lung and Blood Institute is supporting the three-year clinical trial of GMI-1271, an E-selectin antagonist that preliminary data shows prevents blood clot formation and reduces thrombus weight by 50-60 percent.

Co-principal investigators at the U-M are Suman Sood, M.D., a hematologist at the University of Michigan Comprehensive Cancer Center, and Thomas Wakefield, M.D., head of vascular surgery at the U-M Frankel Cardiovascular Center.

VTE, which can happen after a major operation, or severe illness such as heart attacks, stroke and some cancers, refers to both pulmonary embolism and deep vein thrombosis (DVT), blood clots that form in large veins of the legs. The clots become dangerous when they break loose and affect blood flow to the heart and lungs.

A mainstay of VTE prevention and treatment are anticoagulants that reduce blood clotting. But the medicines are associated with a significant risk of hemorrhage and for the most part do not decrease the inflammation that comes with VTE.

"The use of E-selection inhibition has a high therapeutic potential to decrease both thrombosis and its harmful inflammatory effects," says Sood.

GMI-1271 inhibits the cell-cell interactions that provide the scaffolding for blood clots to form. The compound is in the pipeline of drugs developed by GlycoMimetics, Inc., a clinical stage biotechnology company.

"We hypothesize that use of an E-selection inhibitor in patients with acute DVT, either alone or in combination with traditional anticoagulants, may lead to a greater thrombus resolution, higher rates of preserved valve competence, reduced pain and swelling and improved quality of life," says Wakefield.

Enrollment in the phase 1 clinical trial at the U-M is expected to begin in mid-2014 and to include healthy volunteers and those with calf level DVT.

On the Web:
University of Michigan Frankel Cardivascular Center
, Inc.

SOURCE University of Michigan Health System
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Otonomy Enrolls First Patient in Pivotal Phase 2b Study of OTO-104 in Menieres Disease
2. Avanir Pharmaceuticals Announces Results for Phase II PRIME Study
3. AbbVie Demonstrates 96 percent SVR(12) in its Phase III Study of Treatment-Experienced Patients with Genotype 1 Hepatitis C
4. New Study: Medicare Preferred Pharmacy Network Plans Offer Lower Average Premiums, Same Quality as Non-Preferred Network Plans
5. Upsher-Smith Debuts Positive Results From Global Phase 3 Study Evaluating USL255 (extended-release topiramate) In Epilepsy Patients With Refractory Partial-Onset Seizures
6. New Study Finds Targeted Treatment Can Significantly Reduce Relapse Risk In High-Risk Children With Acute Myeloid Leukemia
7. Heptares Initiates Clinical Study With First Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Patients With Alzheimers Disease
8. Shire Reports Top-Line Results on OPUS-2, a Phase 3 Study Investigating the Use of Lifitegrast (5.0% Ophthalmic Solution) in Adults With Dry Eye Disease
9. Third Clinical Study Confirms Treatment Guided By GeneSight Psychiatric Pharmacogenomics Test
10. Study Confirms Efficacy of Innovative Therapies Quantum Negative Pressure Wound Therapy (NPWT) in Enhancing Wound Healing
11. Annual General Meeting Schedules, New Drug Applications, Positive Study Results, Conference Participations, and Secondary Offerings - Research Report on Mindray, AcelRx, Merrimack, ZELTIQ, and Clovis
Post Your Comments:
(Date:10/12/2015)... 12, 2015 Device usage in healthcare continues ... integrate these devices into existing clinical workflow. In response, ... and mobility solutions, has launched the SV10 series of ... a wide array of laptops and tablets. In addition, ... exclusively for Microsoft Surface and is compatible with all ...
(Date:10/12/2015)... October 12, 2015 ... to grow at 7.2% CAGR, microscopy market ... rising focus on nanotechnology, technological advancements, and ... report available with ... . --> Complete report on ...
(Date:10/12/2015)... Oct. 12, 2015 Indivior PLC (LON: INDV) today ... Delaware granted the Company,s motion to ... New Drug Application (ANDA) No. 205299 to market a generic ... naloxone) Sublingual Film (CIII) in the United States ... Since August 2013, Indivior has received Paragraph IV certifications from ...
Breaking Medicine Technology:
(Date:10/12/2015)... ... October 12, 2015 , ... ... on being awarded a contract with the U.S. Biomedical Advanced Research and Development ... development and procurement of its ReCell® Autologous Cell Harvesting Device under a U.S. ...
(Date:10/12/2015)... ... October 12, 2015 , ... The translation for ARIS® 7.x ... migration of complete ARIS installations into the Microsoft world. The ARIS models will be ... Visio® is very familiar for both IT and Office users it is acknowledged as ...
(Date:10/12/2015)... ... October 12, 2015 , ... The ... to 8:00 pm at the Sheraton Philadelphia Hotel, 3549 Chestnut Street, Philadelphia, PA ... attending from across the country. All specialties will be represented. Attendees will enjoy ...
(Date:10/12/2015)... Greifensee, Switzerland (PRWEB) , ... October 12, 2015 ... ... of new product upgrades designed to streamline laboratory processes. In addition, METTLER TOLEDO ... a free Lean Lab Checklist to help improve productivity through the ...
(Date:10/12/2015)... ... ... On Sept. 26, the team at Dynamic Fitness joined supporters from 58 ... Houston Zoo during September's Childhood Cancer Awareness Month. The Walk/Run helped to raise funds ... up with the idea to involve his team with the walk in an effort ...
Breaking Medicine News(10 mins):